AUKI Pharma ApS
APSDissolvedAdvertising protectionCVR 43030493Tjørnevænget 1, 7130 JuelsmindeManufacture of other food products n.e.c.· NACE 1089Est. 2022 · 4 years old1 employees
Loading company…
Overview
AUKI Pharma ApS is a Danish APS based in Juelsminde, operating in the Manufacture of other food products n.e.c. sector. Incorporated in 2022, the company has 1 employee and reported revenue of DKK 5.4k in its latest annual filing.
Revenue 2023
0M DKK
−91% vs 2022
EBITDA margin
−191.0 %
+19% vs 2022
Net profit 2023
-0M DKK
+48% vs 2022
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
-0.9 %
Very weakAmong the 20% lowest rated companies in the industry
20222023
Liquidity ratioCurrent assets ÷ Short-term debt
0.1×
Very weakAmong the 10% lowest rated companies in the industry
20222023
Return on assets (ROA)Net profit ÷ Total assets × 100
-1.1 %
WeakAmong the 40% lowest rated companies in the industry
20222023
EBITDA — year on year
DKK thousandsKey figures
Annual report 2023| Revenue | 0M DKK | -91% |
| EBITDA | -0M DKK | +19% |
| Net profit | -0M DKK | +48% |
| Total assets | 1.7M DKK | 0% |
| Equity | -0M DKK | -590% |
| Employees | 1 | — |
Company information
Legal name
AUKI Pharma ApS
CVR number
43030493
Legal form
Anpartsselskab
NACE code
Founded
1 February 2022 · 4 years
Share capital
DKK 40,000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Contact
Address
Tjørnevænget 1, 7130 Juelsminde
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2023), AUKI Pharma ApS reported revenue of DKK 5.4k, a decrease of 91% on the year before. The figures on this page draw on 2 annual filings covering 2022 to 2023. The bottom line showed a net loss of DKK 19.2k, and the EBITDA margin stood at -191%.
At the end of 2023, current assets covered short-term debt 0.1 times.
Financials
Revenue
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2023 | 2022 |
|---|---|---|
| Revenue | 5 | 57 |
| Staff expenses | -0 | -70 |
| EBITDA | -10 | -13 |
| Depreciation & amort. | -0 | -14 |
| EBIT | -10 | -27 |
| Net financials | -9 | -10 |
| Profit before tax | -19 | -37 |
| Tax | -0 | -0 |
| Net profit | -19 | -37 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2023 | 2022 |
|---|---|---|
| Total assets | 1,697 | 1,703 |
| Equity | -16 | 3 |
| Long-term debt | 0 | 0 |
| Short-term debt | 1,713 | 1,700 |
| Total debt | 1,713 | 1,700 |
Financial ratios
5-year trendEBITDA margin
-191.0 %
20222023
Equity ratio
-0.9 %
Very weakAmong the 20% lowest rated companies in the industry
20222023
Return on equity
—
20222023
Net profit margin
-356.0 %
Very weakAmong the 10% lowest rated companies in the industry
20222023
Asset turnover
0.00×
Very weakAmong the 20% lowest rated companies in the industry
20222023
Debt / equity
—
20222023
Sector performance
21 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery strong
Among the 20% highest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery weak
Among the 10% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery weak
Among the 10% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on assets (ROA)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Weak
Among the 40% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 20% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Liquidity
Current ratioVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery weak
Among the 10% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery weak
Among the 20% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 20% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtWeak
Among the 40% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest rate on debtVery strong
Among the 10% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Efficiency & development
Asset turnoverVery weak
Among the 20% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverVery strong
Among the 10% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery weak
Among the 20% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (3)
LL Management | Management | 2024 – 2025 |
EE Management | Management | 2022 – 2024 |
YH Founder | Founder | 2022 – 2025 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
A-WELL LIMITED | Company | 66.67–89.99% | 66.67–89.99% | 2023 |
| Individual | 20–24.99% | 20–24.99% | 2023 | |
| Individual | 50–66.65% | 50–66.65% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
A-Well Limited66.67%
AUKI Pharma ApS (this company)Board network connections
Board members of AUKI Pharma ApS also hold positions in 3 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Larsen | Management | 3 companies |
Frequently asked questions
What is the CVR number of AUKI Pharma ApS?
AUKI Pharma ApS is registered with CVR / Virk under CVR 43030493.
What is the revenue of AUKI Pharma ApS?
AUKI Pharma ApS reported revenue of DKK 5.4k in 2023.
How many employees does AUKI Pharma ApS have?
AUKI Pharma ApS employs 1 people as of the latest annual report.
Where is AUKI Pharma ApS headquartered?
AUKI Pharma ApS's registered address is Tjørnevænget 1.